Davy James, Managing Editor

T cells derived from lymph nodes expanded and activated in a laboratory before being injected back into patients.

Decreased connectivity in network specific regions of brain at the core of cognitive changes.

New culturing method leads to highly therapeutic cells that grow faster and stronger.

Methotrexate alone superior in efficacy to combination treatment with DMARDs.

Five pivotal phase 3 trial ongoing for oral proteasome inhibitor.

Envarsus protects against organ rejection in transplant patients who switch from other twice-daily tacrolimus products.

Pfizer executive discusses the present and future of biosimilars.

Drug could be less expensive to produce and less harmful to healthy cells.

Mitali Nagrecha, counsel at Bergen Pharmacy, discusses tactics specialty pharmacies can use to maintain medication adherence.

Pazopanib shows promise in soft tissue sarcoma patients.

Stem cells have been found to target inflammation in osteoarthritis or rheumatoid arthritis.

Top stories of the week on Specialty Pharmacy Times from July 6 to July 10.

Premature aging of the lung cells plays a factor in pathogenesis.

Exchange plan spending on hepatitis C drugs increased 96% in the first quarter of 2015.

Ron Lanton III, Esq, president of True North Political Solutions, LLC, discusses how specialty pharmacy has been affected by HIPAA laws.

Discovery may lead to cost effective treatment options.

Complete protection seen in half of non-human primates vaccinated against repeated challenges with simian immunodeficiency virus.

Nivolumab and ipilmumab help immune system to shrink tumors.

Fiona Smythe, vice president of strategy at mscripts, discusses developing trends in mobile health care applications.

Tumor suppressing molecule that prevents growth could lead to personalized therapy.

Hydrogel prevents drugs from prematurely leaving the body.

Top stories of the week on Specialty Pharmacy Times from June 29 through July 3.

Lung function and health status decreases across all levels of severity.

Patients face significant financial burdens from treatment.

CEO of Avella Specialty Pharmacy Rebecca M. Shanahan, Esq., discusses how specialty pharmacies can best manage the rising cost of specialty drugs to improve outcomes for patients.

Drug targets the cause of the disease in people who have two copies of a specific mutation.

Coverage restrictions on wrong side of Medicaid law requiring states to cover drugs consistent with FDA labels.

Ocrelizumab may shift MS treatment paradigm.

There are currently more than 600 trials of biosimilars ongoing.

Patients with genotype 1b hepatitis C achieve sustained virologic response after 12 weeks.